Cargando…

Late relapsing germ cell tumors with elevated tumor markers

PURPOSE: Late relapsing germ cell tumors (LR-GCT) are considered a rare distinct biologic entity as their clinical presentation and response to treatment is different to early recurrences. While serum tumor markers (AFP and ß-HCG) play an important role at the time of first diagnosis to correctly cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Che, Yue, Lusch, Achim, Winter, Christian, Große Siemer, Robert, Buddensieck, Carolin, Albers, Peter, Hiester, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921136/
https://www.ncbi.nlm.nih.gov/pubmed/34518930
http://dx.doi.org/10.1007/s00345-021-03833-z
_version_ 1784669272453152768
author Che, Yue
Lusch, Achim
Winter, Christian
Große Siemer, Robert
Buddensieck, Carolin
Albers, Peter
Hiester, Andreas
author_facet Che, Yue
Lusch, Achim
Winter, Christian
Große Siemer, Robert
Buddensieck, Carolin
Albers, Peter
Hiester, Andreas
author_sort Che, Yue
collection PubMed
description PURPOSE: Late relapsing germ cell tumors (LR-GCT) are considered a rare distinct biologic entity as their clinical presentation and response to treatment is different to early recurrences. While serum tumor markers (AFP and ß-HCG) play an important role at the time of first diagnosis to correctly classify prognosis and treatment of germ cell tumors, they may not have the same significance in a late relapse situation. PATIENTS AND METHODS: Thirty-seven patients with LR-GCT with elevated serum tumor markers were identified in our database. Twenty-six patients underwent primary surgical resection of the late relapsing tumor. Eleven patients received salvage chemotherapy and a post-chemotherapy residual tumor resection. Serum tumor markers, histological findings and oncological outcome were analyzed. RESULTS: In the histopathological specimen, viable cancer was found in 20 cases (54%) and teratoma was found in 16 cases (43%). In nine cases (24%), a somatic-type malignant transformation was present. In 19 of 37 patients (51.4%), the late relapse specimen presented a histological type of GCT, which was not present in the primary histology. Twenty-two patients (59.5%) were included in follow-up analysis. Mean and median follow-up time was 62.2 and 53 months, respectively. Seventeen patients (77.3%) suffered a relapse or had progressive disease after LR therapy. Five patients (22.7%) have been relapse-free after LR therapy (mean FU 61.6 months). Ten patients died of disease during follow-up (45.5%) and had a mean time from LR to death of 66.4 months. Eleven patients were alive at last follow-up (mean FU 62.2 months). Relapse and survival rate were similar between patients who received primary resection of LR tumor and patients who received salvage chemotherapy followed by surgery. CONCLUSION: Patients with a late relapsing germ cell tumor and elevated markers have a poor prognosis and a high risk for another relapse independent on primary treatment. The histological type and aggressiveness of a late relapsing tumor cannot be predicted with serum tumor marker levels at the time of diagnosis of LR. In up to 54% of cases, primary histology did not coincide with LR histology. Therefore, we propose primary surgical resection of a late relapsing tumor if a complete resection is feasible in order to gain exact histology and tailor further treatment.
format Online
Article
Text
id pubmed-8921136
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-89211362022-03-17 Late relapsing germ cell tumors with elevated tumor markers Che, Yue Lusch, Achim Winter, Christian Große Siemer, Robert Buddensieck, Carolin Albers, Peter Hiester, Andreas World J Urol Topic Paper PURPOSE: Late relapsing germ cell tumors (LR-GCT) are considered a rare distinct biologic entity as their clinical presentation and response to treatment is different to early recurrences. While serum tumor markers (AFP and ß-HCG) play an important role at the time of first diagnosis to correctly classify prognosis and treatment of germ cell tumors, they may not have the same significance in a late relapse situation. PATIENTS AND METHODS: Thirty-seven patients with LR-GCT with elevated serum tumor markers were identified in our database. Twenty-six patients underwent primary surgical resection of the late relapsing tumor. Eleven patients received salvage chemotherapy and a post-chemotherapy residual tumor resection. Serum tumor markers, histological findings and oncological outcome were analyzed. RESULTS: In the histopathological specimen, viable cancer was found in 20 cases (54%) and teratoma was found in 16 cases (43%). In nine cases (24%), a somatic-type malignant transformation was present. In 19 of 37 patients (51.4%), the late relapse specimen presented a histological type of GCT, which was not present in the primary histology. Twenty-two patients (59.5%) were included in follow-up analysis. Mean and median follow-up time was 62.2 and 53 months, respectively. Seventeen patients (77.3%) suffered a relapse or had progressive disease after LR therapy. Five patients (22.7%) have been relapse-free after LR therapy (mean FU 61.6 months). Ten patients died of disease during follow-up (45.5%) and had a mean time from LR to death of 66.4 months. Eleven patients were alive at last follow-up (mean FU 62.2 months). Relapse and survival rate were similar between patients who received primary resection of LR tumor and patients who received salvage chemotherapy followed by surgery. CONCLUSION: Patients with a late relapsing germ cell tumor and elevated markers have a poor prognosis and a high risk for another relapse independent on primary treatment. The histological type and aggressiveness of a late relapsing tumor cannot be predicted with serum tumor marker levels at the time of diagnosis of LR. In up to 54% of cases, primary histology did not coincide with LR histology. Therefore, we propose primary surgical resection of a late relapsing tumor if a complete resection is feasible in order to gain exact histology and tailor further treatment. Springer Berlin Heidelberg 2021-09-13 2022 /pmc/articles/PMC8921136/ /pubmed/34518930 http://dx.doi.org/10.1007/s00345-021-03833-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Topic Paper
Che, Yue
Lusch, Achim
Winter, Christian
Große Siemer, Robert
Buddensieck, Carolin
Albers, Peter
Hiester, Andreas
Late relapsing germ cell tumors with elevated tumor markers
title Late relapsing germ cell tumors with elevated tumor markers
title_full Late relapsing germ cell tumors with elevated tumor markers
title_fullStr Late relapsing germ cell tumors with elevated tumor markers
title_full_unstemmed Late relapsing germ cell tumors with elevated tumor markers
title_short Late relapsing germ cell tumors with elevated tumor markers
title_sort late relapsing germ cell tumors with elevated tumor markers
topic Topic Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921136/
https://www.ncbi.nlm.nih.gov/pubmed/34518930
http://dx.doi.org/10.1007/s00345-021-03833-z
work_keys_str_mv AT cheyue laterelapsinggermcelltumorswithelevatedtumormarkers
AT luschachim laterelapsinggermcelltumorswithelevatedtumormarkers
AT winterchristian laterelapsinggermcelltumorswithelevatedtumormarkers
AT großesiemerrobert laterelapsinggermcelltumorswithelevatedtumormarkers
AT buddensieckcarolin laterelapsinggermcelltumorswithelevatedtumormarkers
AT alberspeter laterelapsinggermcelltumorswithelevatedtumormarkers
AT hiesterandreas laterelapsinggermcelltumorswithelevatedtumormarkers